As antibiotic-resistant infections continue to claim more than a million lives globally each year, scientists and clinicians are increasingly turning to a century-old idea reborn in modern laboratories: bacteriophage therapy. Recent clinical successes and a wave of regulatory progress in 2025 are pushing the once-fringe approach closer to mainstream medicine, with researchers in the United States, Belgium, and Australia reporting breakthroughs in treating patients whom conventional antibiotics had failed.

Bacteriophages — viruses that infect and kill bacteria — were first described in the early 20th century, but their development as therapeutics largely stalled in the West after the discovery of penicillin. Now, with the World Health Organization warning that antimicrobial resistance is one of the top global public health threats facing humanity, phages are being reconsidered as a precision tool capable of targeting specific bacterial strains while leaving the broader microbiome intact.

A Renewed Clinical Push

Multiple academic medical centers have launched compassionate-use programs and clinical trials this year. The Center for Innovative Phage Applications and Therapeutics at the University of California, San Diego — co-founded after a now-famous 2016 case in which phages saved a patient with a multi-drug-resistant Acinetobacter baumannii infection — has continued to expand its caseload, with researchers reporting positive outcomes in patients with cystic fibrosis lung infections and prosthetic joint infections.

In Belgium, the Queen Astrid Military Hospital remains one of the few centers in the world routinely producing personalized phage cocktails under a national magistral preparation framework. Clinicians there have argued that this regulatory model, which treats phages somewhat like compounded pharmacy preparations, allows faster patient access than the traditional drug-approval pathway used by the U.S. Food and Drug Administration.

Why This Matters

The urgency behind these efforts is hard to overstate. A landmark analysis published in The Lancet estimated that bacterial antimicrobial resistance was directly responsible for approximately 1.27 million deaths in 2019, with projections suggesting that figure could climb sharply by mid-century if no new tools emerge. Pharmaceutical pipelines for novel antibiotics have thinned dramatically, in part because of weak commercial incentives — a problem detailed in repeated reports by the Pew Charitable Trusts.

Phages offer several advantages that synthetic antibiotics cannot easily match. Because they evolve alongside their bacterial hosts, they can in principle be updated to keep pace with resistance. They are also exquisitely specific, often targeting a single bacterial species or strain, which spares beneficial microbes that broad-spectrum antibiotics indiscriminately destroy. That specificity, however, is also their commercial Achilles’ heel: a treatment that works for one patient’s Pseudomonas aeruginosa may be useless for another’s, complicating mass production and standardized clinical trials.

Expert Voices and Caution

Researchers stress that enthusiasm must be tempered by rigorous science. Steffanie Strathdee, the UCSD epidemiologist whose husband’s recovery helped catalyze the modern phage revival, has repeatedly cautioned that phage therapy is not a silver bullet and that randomized controlled trials remain essential. Several such trials — including one targeting diabetic foot ulcer infections and another for chronic respiratory infections — are now enrolling patients, with early data expected within the next 18 months.

Meanwhile, regulators are quietly working on frameworks suited to a therapy that resists one-size-fits-all approval. The European Medicines Agency has held workshops on the unique challenges of regulating personalized biologicals, and the FDA has signaled willingness to consider adaptive pathways for phage products in life-threatening cases.

What to Watch Next

The next year will likely prove decisive. Results from larger controlled trials, decisions on regulatory pathways, and continued investment from biotech firms developing engineered phages and phage-derived enzymes — known as lysins — will determine whether bacteriophage therapy graduates from heroic salvage treatment to a standard option in the clinician’s toolkit. If it does, it could reshape the way infectious disease is treated in an era when our most reliable drugs are quietly losing their power.

For more reporting on emerging microbiology research, antimicrobial resistance, and the science shaping global health, visit science.wide-ranging.com for related coverage and in-depth features.